Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week PK, safety, and pharmacodynamic study of teduglutide in pediatric short bowel syndrome dependent on parenteral support
2013-004588-30Phase 3Completed
- Sponsor
- NPS Pharmaceuticals, Inc.
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of teduglutide in short bowel syndrome (SBS) (2 arms), sponsored by NPS Pharmaceuticals, Inc. Primary endpoint: Pharmacokinetic parameters. Started Jan 2014; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2013-004588-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004588-30.